JP2019507791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507791A5 JP2019507791A5 JP2018547929A JP2018547929A JP2019507791A5 JP 2019507791 A5 JP2019507791 A5 JP 2019507791A5 JP 2018547929 A JP2018547929 A JP 2018547929A JP 2018547929 A JP2018547929 A JP 2018547929A JP 2019507791 A5 JP2019507791 A5 JP 2019507791A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- dihydroxybutan
- sulfonamide
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078242A JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307348P | 2016-03-11 | 2016-03-11 | |
| US62/307,348 | 2016-03-11 | ||
| PCT/US2017/021570 WO2017156270A1 (en) | 2016-03-11 | 2017-03-09 | Cxcr-2 inhibitors for treating crystal arthropathy disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078242A Division JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507791A JP2019507791A (ja) | 2019-03-22 |
| JP2019507791A5 true JP2019507791A5 (enExample) | 2020-04-30 |
| JP6883917B2 JP6883917B2 (ja) | 2021-06-09 |
Family
ID=59789863
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547929A Expired - Fee Related JP6883917B2 (ja) | 2016-03-11 | 2017-03-09 | 結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤 |
| JP2021078242A Expired - Fee Related JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078242A Expired - Fee Related JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10772886B2 (enExample) |
| EP (1) | EP3426253A4 (enExample) |
| JP (2) | JP6883917B2 (enExample) |
| CN (2) | CN109152780B (enExample) |
| AU (1) | AU2017231832B2 (enExample) |
| BR (1) | BR112018068393A2 (enExample) |
| CA (1) | CA3017345A1 (enExample) |
| CO (1) | CO2018010880A2 (enExample) |
| MX (1) | MX386771B (enExample) |
| WO (1) | WO2017156270A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109152780B (zh) | 2016-03-11 | 2021-10-01 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| AU2018334152A1 (en) * | 2017-09-12 | 2020-04-23 | Ardea Biosciences, Inc. | CXCR-2 inhibitors for treating disorders |
| CN111727184B (zh) | 2018-01-11 | 2022-06-28 | 深圳嘉科生物科技有限公司 | Cxcr2拮抗剂 |
| WO2021004531A1 (zh) * | 2019-07-11 | 2021-01-14 | 南京明德新药研发有限公司 | 一种cxcr2拮抗剂的晶型及其应用 |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| EP4161499A1 (en) * | 2020-06-05 | 2023-04-12 | Aristea Therapeutics, Inc. | Use of a combination of colchicine and a cxcr-2 inhibitor for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof |
| WO2022162021A1 (en) * | 2021-01-27 | 2022-08-04 | Astrazeneca Ab | Verinurad compositions and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| CN1914187B (zh) | 2004-01-30 | 2012-01-25 | 先灵公司 | Cxc趋化因子受体配位体的结晶多晶型物 |
| EP2311827A1 (en) | 2004-08-28 | 2011-04-20 | AstraZeneca AB | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. |
| RU2009131454A (ru) * | 2007-01-19 | 2011-02-27 | Такеда Фармасьютикалз Норт Америка, Инк. (Us) | Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств |
| EP2203432A4 (en) | 2007-09-21 | 2011-04-27 | Glaxosmithkline Llc | PROCESSING METHOD |
| US20090093548A1 (en) | 2007-10-05 | 2009-04-09 | Mutual Pharmaceutical Company, Inc | Colchine compositions and methods |
| EP2252327A2 (en) | 2007-12-04 | 2010-11-24 | Schering Corporation | Methods of treating copd |
| KR20110014141A (ko) | 2008-03-20 | 2011-02-10 | 카롤러스 테라퓨틱스, 인코포레이티드 | 염증을 치료하는 방법 |
| CA2730477A1 (en) | 2008-07-16 | 2010-01-21 | Astrazeneca Ab | Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
| EP2331564A4 (en) | 2008-10-06 | 2013-02-20 | Carolus Therapeutics Inc | PROCESS FOR TREATMENT OF IGNITION |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| WO2010065491A2 (en) | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| EP2421901B1 (en) | 2009-04-24 | 2015-10-28 | Tissue Tech, Inc. | Compositions containing hc ha complex and methods of use thereof |
| WO2011038149A2 (en) | 2009-09-23 | 2011-03-31 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| WO2011116245A2 (en) | 2010-03-19 | 2011-09-22 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| EP2593448A1 (en) | 2010-07-13 | 2013-05-22 | AstraZeneca AB | New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
| AU2011293612B2 (en) * | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| KR101946664B1 (ko) * | 2011-07-12 | 2019-02-11 | 아스트라제네카 아베 | 케모카인 수용체 조절제로서의 n-(6-((2r,3s)-3,4-디히드록시부탄-2-일옥시)-2-(4-플루오로벤질티오)피리미딘-4-일)-3-메틸아제티딘-1-술폰아미드 |
| ES2846789T3 (es) | 2012-07-11 | 2021-07-29 | Tissuetech Inc | Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos |
| EP3220951A1 (en) | 2014-11-17 | 2017-09-27 | MedImmune Limited | Therapeutic combinations and methods for treating neoplasia |
| CN109152780B (zh) | 2016-03-11 | 2021-10-01 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| US20180221312A1 (en) | 2016-03-11 | 2018-08-09 | Ardea Biosciences, Inc. | Cxcr-2 inhibitors for treating disorders |
| AU2018334152A1 (en) | 2017-09-12 | 2020-04-23 | Ardea Biosciences, Inc. | CXCR-2 inhibitors for treating disorders |
-
2017
- 2017-03-09 CN CN201780029205.4A patent/CN109152780B/zh active Active
- 2017-03-09 CA CA3017345A patent/CA3017345A1/en active Pending
- 2017-03-09 EP EP17764095.0A patent/EP3426253A4/en not_active Withdrawn
- 2017-03-09 MX MX2018010946A patent/MX386771B/es unknown
- 2017-03-09 WO PCT/US2017/021570 patent/WO2017156270A1/en not_active Ceased
- 2017-03-09 BR BR112018068393A patent/BR112018068393A2/pt not_active Application Discontinuation
- 2017-03-09 US US15/516,465 patent/US10772886B2/en not_active Expired - Fee Related
- 2017-03-09 CN CN202111152242.9A patent/CN113893252A/zh active Pending
- 2017-03-09 AU AU2017231832A patent/AU2017231832B2/en not_active Ceased
- 2017-03-09 JP JP2018547929A patent/JP6883917B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-10 CO CONC2018/0010880A patent/CO2018010880A2/es unknown
-
2021
- 2021-05-05 JP JP2021078242A patent/JP7126014B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| KR102159601B1 (ko) | 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 | |
| JP7460772B2 (ja) | コロナウイルス感染症の治療方法 | |
| US20110046119A1 (en) | Therapeutic treatment | |
| JP2015535247A5 (enExample) | ||
| JP2012184234A5 (enExample) | ||
| JP2013528655A5 (enExample) | ||
| BR112015010063A2 (pt) | método para o tratamento ou prevenção de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, utilização de um composto de fórmula (i), um derivado da colquicina conhecido e/ou um sal do mesmo, composição para a prevenção ou tratamento de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, método e regime para reduzir ou prevenir a inflamação induzida por cristal de colesterol no interior das placas ateroscleróticas em um sujeito, regime para o tratamento ou prevenção de um acidente cardiovascular em um indivíduo | |
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| US10973801B2 (en) | Capsid assembly modulator dosing regimen | |
| JP2014532760A5 (enExample) | ||
| JP2021522247A5 (enExample) | ||
| TW201919599A (zh) | 用於治療病症之cxcr-2抑制劑 | |
| MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| JP2019530711A5 (enExample) | ||
| KR20230048517A (ko) | 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법 | |
| WO2003080063A1 (en) | PREVENTIVES OR REMEDIES FOR DISEAES CAUSED BY eNOS EXPRESSION | |
| JP7332589B2 (ja) | 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ | |
| JP2014532759A5 (enExample) | ||
| RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| WO2006104086A1 (ja) | 血栓症治療剤 | |
| JP2015526504A5 (enExample) | ||
| JP2012510470A (ja) | メシル酸イマチニブを用いたフィラデルフィア陽性白血病の処置を最適化する方法 | |
| JP2013526499A (ja) | キサンチンオキシダーゼ阻害剤およびスタチンの合剤およびその使用 | |
| EA202193330A1 (ru) | Способы лечения рака с использованием ингибиторов prmt5 |